Compare Biogen Inc (BIIB) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs ProShares UltraPro Short QQQ ETF — how do they compare? Biogen Inc trades at $193.28 (market cap $28.34B), while ProShares UltraPro Short QQQ ETF trades at $39.2. The key difference: Biogen Inc is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.
| BIIB | SQQQ | |
|---|---|---|
Market Cap | $28.34B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $216.63 | $97.60 |
52-Week Low | $122.68 | $36.31 |
Enterprise Value | $30.62B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
SQQQ (ProShares UltraPro Short QQQ ETF) trades at $39.95, up 5.74% ($2.17) in the last session. The ETF shows a neutral technical signal overall with bullish moving averages and neutral oscillators. Recent news highlights SQQQ's role as a tactical hedging tool against Nasdaq 100 declines, though long-term performance erosion due to daily -3x leverage remains a concern. Short interest increased 19.4% in March 2026, reflecting bearish sentiment toward tech.
Outlook: SQQQ is a high-risk, short-term instrument for hedging QQQ exposure, not a long-term investment. Opportunities exist for tactical investors during tech selloffs, but risks include volatility decay, timing challenges, and structural erosion. Investors should understand the leveraged ETF's mechanics and use it cautiously within a diversified strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
